gene therapy industry

gene therapy industry

featured image of Unlocking the Secrets of LNPs: Nano-Flow Cytometry Reveals All

Unlocking the Secrets of LNPs: Nano-Flow Cytometry Reveals All

BIOT

📢 Comprehensive LNP Characterization from Cargo to Target Modification Using Nano-Flow Cytometry explores innovative techniques for analyzing lipid nanoparticles. 🔬🚀💊🔍✨

featured image of RevIT AAV: Transforming Gene Therapy Production Efficiency

RevIT AAV: Transforming Gene Therapy Production Efficiency

BIOT

🔍Discover RevIT AAV: A game-changing enhancer for gene therapy production, increasing efficiency by 2-4X. 🧬🔬🧪

featured image of MilliporeSigma Acquires Mirus Bio for $600 Million Expanding in Gene Therapy Market

MilliporeSigma Acquires Mirus Bio for $600 Million Expanding in Gene Therapy Market

BIOT

MilliporeSigma 💪 powers up with $600M acquisition of Mirus Bio! 📆 Closing in Q3 2024. 😮 CellAndGeneTherapy BiotechNews

featured image of Revolutionary Company Solves Manufacturing Failures for Gene Therapy

Revolutionary Company Solves Manufacturing Failures for Gene Therapy

BIOT

📢 Introducing Bespark*bio: Tackling manufacturing failures in gene therapy to bring life-saving treatments to the market! 🏭💡💉

featured image of CEO of Généthon Reveals Future of Gene Therapy

CEO of Généthon Reveals Future of Gene Therapy

BIOT

🔍 Frédéric Revah, CEO of Généthon, reflects on the past, present, and future of the organization in an interview. 🧬 Généthon was created in 1990 with a focus on gene therapy research for rare genetic diseases. 💡 Revah discusses the challenges of financing development for rare diseases and the need for equity in distribution. 🏭 Généthon is working on improving bioprocessing and reducing the cost of production for gene therapies. 🤝 The organization collaborates with partners in various fields to advance their research. ⚙️ Exciting developments include producing AAV in plants and using artificial intelligence to optimize bioreactors. ❌ The industry faces challenges such as improving the full-to-empty ratio of virus capsids. ❗️ Revah comments on the Pfizer incident and assures that Généthon is closely monitoring safety in their own clinical trial.

featured image of Revolutionary Mass Photometry Boosts Gene Therapy Quality

Revolutionary Mass Photometry Boosts Gene Therapy Quality

BIOT

🌟✨ Mass photometry is a game-changer for gene therapy companies, providing accurate assessments without labeling or long run times. 🧬💡

featured image of Revolutionary Alliance Launches AI-Driven Eye Therapy

Revolutionary Alliance Launches AI-Driven Eye Therapy

BIOT

👀 Three companies join forces to develop gene therapy for eye diseases, using AI and machine learning algorithms. 🧬👁️🔬

featured image of Revolutionary Automation System Cuts Cell and Gene Therapy Costs by 70

Revolutionary Automation System Cuts Cell and Gene Therapy Costs by 70

BIOT

🤖 Vendor-agnostic automation system for cell and gene therapy manufacturing reduces errors and lowers costs.💡

featured image of Revolutionary Standardized Viral Vector Manufacturing for Gene Therapy

Revolutionary Standardized Viral Vector Manufacturing for Gene Therapy

BIOT

📰 AGC Biologics offers standardized viral vector manufacturing, covering the entire process from transfection to purification. 🔬💡🌐

featured image of Gene Therapy Revolution: The Power of ssDNA

Gene Therapy Revolution: The Power of ssDNA

BIOT

🌟 The Emerging Role of ssDNA in Gene Therapy 🌟 Discover how single-stranded DNA is revolutionizing gene therapy, democratizing treatments and expanding accessibility. 🧪🔬✨